Renaissance Technologies LLC Lowers Stock Holdings in Haleon plc (NYSE:HLN)

Renaissance Technologies LLC trimmed its position in shares of Haleon plc (NYSE:HLN - Free Report) by 42.2% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 613,099 shares of the company's stock after selling 448,300 shares during the period. Renaissance Technologies LLC's holdings in Haleon were worth $5,849,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the company. FIL Ltd boosted its holdings in Haleon by 45.7% during the 4th quarter. FIL Ltd now owns 4,049 shares of the company's stock valued at $39,000 after acquiring an additional 1,270 shares during the period. Cerity Partners LLC lifted its position in shares of Haleon by 1.3% during the fourth quarter. Cerity Partners LLC now owns 584,164 shares of the company's stock worth $5,946,000 after purchasing an additional 7,631 shares in the last quarter. FMR LLC boosted its stake in shares of Haleon by 3.7% in the fourth quarter. FMR LLC now owns 108,827,814 shares of the company's stock valued at $1,038,217,000 after purchasing an additional 3,909,545 shares during the period. Quadrant Capital Group LLC grew its holdings in shares of Haleon by 6.5% in the fourth quarter. Quadrant Capital Group LLC now owns 48,829 shares of the company's stock valued at $466,000 after purchasing an additional 3,001 shares in the last quarter. Finally, Russell Investments Group Ltd. increased its stake in Haleon by 1.3% during the 4th quarter. Russell Investments Group Ltd. now owns 995,241 shares of the company's stock worth $9,495,000 after buying an additional 12,731 shares during the period. 6.67% of the stock is currently owned by hedge funds and other institutional investors.

Haleon Stock Performance

NYSE HLN traded up $0.05 during trading hours on Thursday, hitting $10.28. The company had a trading volume of 6,249,529 shares, compared to its average volume of 7,241,431. The business has a 50 day moving average of $10.12 and a 200-day moving average of $9.81. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.58 and a current ratio of 0.84. Haleon plc has a 1-year low of $8.12 and a 1-year high of $10.80. The company has a market cap of $46.40 billion, a PE ratio of 30.22, a price-to-earnings-growth ratio of 2.82 and a beta of 0.24.

Haleon (NYSE:HLN - Get Free Report) last issued its quarterly earnings data on Thursday, February 27th. The company reported $0.05 earnings per share for the quarter. The company had revenue of $3.54 billion during the quarter, compared to analysts' expectations of $3.38 billion. Haleon had a return on equity of 14.76% and a net margin of 10.85%. As a group, equities research analysts expect that Haleon plc will post 0.43 EPS for the current year.

Haleon Increases Dividend

The firm also recently disclosed a -- dividend, which will be paid on Thursday, June 5th. Shareholders of record on Friday, April 25th will be given a dividend of $0.1166 per share. This is an increase from Haleon's previous -- dividend of $0.05. This represents a yield of 1.6%. The ex-dividend date of this dividend is Friday, April 25th. Haleon's dividend payout ratio (DPR) is presently 58.97%.

Wall Street Analyst Weigh In

Several equities analysts have commented on HLN shares. Morgan Stanley cut shares of Haleon from an "overweight" rating to an "equal weight" rating in a research report on Friday, January 10th. Hsbc Global Res lowered Haleon from a "strong-buy" rating to a "hold" rating in a report on Wednesday, March 5th. HSBC restated a "hold" rating on shares of Haleon in a report on Wednesday, March 5th. Sanford C. Bernstein cut Haleon from an "outperform" rating to a "market perform" rating in a research note on Wednesday, January 8th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating on shares of Haleon in a report on Monday, March 3rd. Six investment analysts have rated the stock with a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus target price of $10.95.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.